Management of Elevated D-dimer in Patients with Pneumonia or Cancer

Introduction to D-dimer Limitations

The European Respiratory Society and the National Comprehensive Cancer Network recommend assessing clinical probability of venous thromboembolism (VTE) using validated scoring systems and proceeding directly to imaging, rather than relying on D-dimer alone, in patients with pneumonia or cancer presenting with elevated D-dimer, due to its severely limited diagnostic utility in these populations 1, 2
D-dimer is frequently elevated in cancer patients regardless of VTE status, with the number needed to test to exclude one PE rising from 3 in the general emergency department population to ≥10 in cancer patients, according to the European Respiratory Society 1
The false-positive rate is 3-fold higher in cancer patients compared to non-cancer patients, and current guidelines from the National Comprehensive Cancer Network explicitly discourage routine D-dimer testing for VTE diagnosis in cancer patients 2

The European Heart Journal recommends using the Wells score or revised Geneva score to categorize patients into low, intermediate, or high clinical probability categories before interpreting any D-dimer result, with a strength of evidence rated as high 3, 4
For high clinical probability patients, the European Respiratory Journal and the European Heart Journal recommend proceeding directly to CT pulmonary angiography (CTPA) without D-dimer testing, as D-dimer has low negative predictive value in this population, with a strength of evidence rated as moderate 1, 4
For intermediate clinical probability patients, the National Comprehensive Cancer Network and the European Heart Journal recommend proceeding to imaging (CTPA for suspected PE or whole-leg ultrasound for suspected DVT) rather than D-dimer testing, given the limited utility in cancer and pneumonia populations, with a strength of evidence rated as low 2, 5

Active cancer is worth 2 points in the Wells score, automatically placing most cancer patients into at least intermediate clinical probability, according to the European Respiratory Journal, with a strength of evidence rated as high 1
The European Respiratory Journal recommends using age-adjusted cutoffs (age × 10 ng/mL) for patients >50 years to improve specificity while maintaining >97% sensitivity, with a strength of evidence rated as moderate 1, 3
The National Comprehensive Cancer Network and the European Heart Journal recommend never using a positive D-dimer alone to diagnose VTE in cancer or pneumonia patients, and confirmation with imaging is always required, with a strength of evidence rated as high 2, 5